Laurel A. Habel, PhD

home / authors / laurel-a-habel-phd

Articles

May 17th 2016

Breast Cancer Multigene Testing Trends and Impact on Chemotherapy Use

G. Thomas Ray, MBA Jeanne Mandelblatt, MD Laurel A. Habel, PhD Scott Ramsey, MD, PhD Lawrence H. Kushi, ScD Yan Li, MD Tracy A. Lieu, MD, MPH

A multigene test for breast cancer recurrence risk was used in a minority of eligible patients, yet was associated with a decrease in chemotherapy use.

November 20th 2012

Utilization of HER2 Genetic Testing in a Multi-Institutional Observational Study

Katrina A.B. Goddard, PhD Erin J. Aiello Bowles, MPH Heather Spencer Feigelson, PhD, MPH Laurel A. Habel, PhD Sharon Hensley Alford, PhD Catherine A. McCarty, PhD, MPH Larissa Nekhlyudov, MD, MPH Adedayo A. Onitilo, MD, MSCR, FACP Alanna K. Rahm, PhD, MS Jennifer A. Webster, MS

Evaluation of real-world implementation of HER2 testing showed that uptake was high (>90%) and trastuzumab treatment was targeted to patients with positive HER2 status.

May 11th 2010

Treatment of Ductal Carcinoma In Situ Among Patients Cared for in Large Integrated Health Plans

Reina Haque, PhD Ninah S. Achacoso, MS Suzanne W. Fletcher, MD, MSc Larissa Nekhlyudov, MD, MPH Laura C. Collins, MBBS Stuart J. Schnitt, MD Charles P. Quesenberry Jr, PhD Laurel A. Habel, PhD

Although we found no DCIS treatment disparities by race/ethnicity, use of adjuvant radiation therapy was less among older women and among residents of poorer neighborhoods.